Mandaviya addresses Second G20 Health Ministers Meet
He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods
He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
Subscribe To Our Newsletter & Stay Updated